| Melissa E Wood, CFNP | |
|
106 Clinton Pkwy, Clinton, MS 39056-4730 | |
| (601) 924-9005 | |
| (601) 925-9463 |
| Full Name | Melissa E Wood |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner - Family |
| Location | 106 Clinton Pkwy, Clinton, Mississippi |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1578795134 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LF0000X | Nurse Practitioner - Family | A003283 (Arkansas) | Secondary |
| 363LF0000X | Nurse Practitioner - Family | R901008 (Mississippi) | Primary |
| Entity Name | Medical Foundation Of Central Mississippi Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1992774814 PECOS PAC ID: 1153216411 Enrollment ID: O20040217000380 |
News Archive
Today's headlines include a report that congressional conservatives are fighting amongst themselves over health law strategies.
Vtesse, Inc. announced today that the U.S. Food and Drug Administration has granted its drug candidate, VTS-270 for treatment of Niemann-Pick Type C1 Disease (NPC), Breakthrough Therapy designation status. Both the FDA and the European Medicines Agency (EMA) had previously granted Orphan Drug status to VTS-270, which is currently in a pivotal Phase 2b/3 clinical trial.
With almost one billion people lacking access to clean, safe drinking water, scientists are reporting development and successful initial tests of an inexpensive new filtering technology that kills up to 98 percent of disease-causing bacteria in water in seconds without clogging. A report on the technology appears in Nano Letters, a monthly American Chemical Society journal.
A recent study by a team of scientists at Beth Israel Deaconess Medical Center and Janssen Vaccines & Prevention has demonstrated that humoral and cellular immunity elicited by the coronavirus disease 2019 (COVID-19) vaccine Ad26.COV2.S remains active for at least eight months.
› Verified 3 days ago
| Entity Name | Flowood River Oaks Hma Medical Group, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1801128798 PECOS PAC ID: 5890825004 Enrollment ID: O20100615000668 |
News Archive
Today's headlines include a report that congressional conservatives are fighting amongst themselves over health law strategies.
Vtesse, Inc. announced today that the U.S. Food and Drug Administration has granted its drug candidate, VTS-270 for treatment of Niemann-Pick Type C1 Disease (NPC), Breakthrough Therapy designation status. Both the FDA and the European Medicines Agency (EMA) had previously granted Orphan Drug status to VTS-270, which is currently in a pivotal Phase 2b/3 clinical trial.
With almost one billion people lacking access to clean, safe drinking water, scientists are reporting development and successful initial tests of an inexpensive new filtering technology that kills up to 98 percent of disease-causing bacteria in water in seconds without clogging. A report on the technology appears in Nano Letters, a monthly American Chemical Society journal.
A recent study by a team of scientists at Beth Israel Deaconess Medical Center and Janssen Vaccines & Prevention has demonstrated that humoral and cellular immunity elicited by the coronavirus disease 2019 (COVID-19) vaccine Ad26.COV2.S remains active for at least eight months.
› Verified 3 days ago
| Entity Name | Mississippi Hma Hospitalists Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1154608883 PECOS PAC ID: 5991972077 Enrollment ID: O20120112000182 |
News Archive
Today's headlines include a report that congressional conservatives are fighting amongst themselves over health law strategies.
Vtesse, Inc. announced today that the U.S. Food and Drug Administration has granted its drug candidate, VTS-270 for treatment of Niemann-Pick Type C1 Disease (NPC), Breakthrough Therapy designation status. Both the FDA and the European Medicines Agency (EMA) had previously granted Orphan Drug status to VTS-270, which is currently in a pivotal Phase 2b/3 clinical trial.
With almost one billion people lacking access to clean, safe drinking water, scientists are reporting development and successful initial tests of an inexpensive new filtering technology that kills up to 98 percent of disease-causing bacteria in water in seconds without clogging. A report on the technology appears in Nano Letters, a monthly American Chemical Society journal.
A recent study by a team of scientists at Beth Israel Deaconess Medical Center and Janssen Vaccines & Prevention has demonstrated that humoral and cellular immunity elicited by the coronavirus disease 2019 (COVID-19) vaccine Ad26.COV2.S remains active for at least eight months.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Melissa E Wood, CFNP 555 Highway 51, Ridgeland, MS 39157-2564 Ph: (601) 856-2383 | Melissa E Wood, CFNP 106 Clinton Pkwy, Clinton, MS 39056-4730 Ph: (601) 924-9005 |
News Archive
Today's headlines include a report that congressional conservatives are fighting amongst themselves over health law strategies.
Vtesse, Inc. announced today that the U.S. Food and Drug Administration has granted its drug candidate, VTS-270 for treatment of Niemann-Pick Type C1 Disease (NPC), Breakthrough Therapy designation status. Both the FDA and the European Medicines Agency (EMA) had previously granted Orphan Drug status to VTS-270, which is currently in a pivotal Phase 2b/3 clinical trial.
With almost one billion people lacking access to clean, safe drinking water, scientists are reporting development and successful initial tests of an inexpensive new filtering technology that kills up to 98 percent of disease-causing bacteria in water in seconds without clogging. A report on the technology appears in Nano Letters, a monthly American Chemical Society journal.
A recent study by a team of scientists at Beth Israel Deaconess Medical Center and Janssen Vaccines & Prevention has demonstrated that humoral and cellular immunity elicited by the coronavirus disease 2019 (COVID-19) vaccine Ad26.COV2.S remains active for at least eight months.
› Verified 3 days ago
Lauren Lanier Guthrie, NP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 102 Friars Cv, Clinton, MS 39056 Phone: 601-383-5583 | |
Mrs. Lakeisha Crye Green, PMHNP-BC Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 901 Highway 80 E, Clinton, MS 39056 Phone: 601-488-9668 | |
Ms. Barbara Ann Bradley, CFNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 1407 Beverly Dr, Clinton, MS 39056 Phone: 601-575-3392 | |
Mrs. Amanda Monique Carson-griffin, FNP-BC Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 590 Springridge Rd, Clinton, MS 39056 Phone: 601-488-8101 | |
Alexis Grabow Strahan, MSN, NP-C Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 106 Clinton Pkwy, Clinton, MS 39056 Phone: 601-924-9005 | |
Elizabeth Clark Allen, CFNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 728 Clinton Pkwy Ste B, Clinton, MS 39056 Phone: 601-200-4800 Fax: 601-200-4805 | |
Jennifer Russum, Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 732 Clinton Pkwy, Clinton, MS 39056 Phone: 601-924-7994 |